4 research outputs found
The efficacy of resveratrol in controlling hypertension: study protocol for a randomized, crossover, double-blinded, placebo-controlled trial
Abstract
Background: Hypertension is a global health concern for which novel treatment strategies are necessary. The aim
of this study is to evaluate the efficacy of resveratrol (trans-3, 5, 4′-trihydroxystilbene, a polyphenol present in
grapes) in controlling blood pressure in participants diagnosed with prehypertension and stage 1 hypertension.
Methods/design: In a randomized, crossover, double-blinded, placebo-controlled study, 50 participants with
prehypertension (diastolic blood pressure and systolic blood pressure, 80–89 mmHg and 120–139 mmHg, respectively)
and 50 participants with stage 1 hypertension (diastolic and systolic, 90–99 mmHg and 140–159 mmHg, respectively)
will be assigned to receive resveratrol (99 % pure, from Biotivia Longevity Bioceuticals LLC Company, USA, in 500 mg
capsules, twice daily for 4 weeks, orally) or placebo (500 mg neutral microcellulose capsules, twice daily for 4 weeks) in
a 2 × 2 crossover design (4 weeks treatment—4 weeks washout—4 weeks treatment). The blood pressure of each
participant will be recorded (a mean of two times within a 15-minute interval) every week during the study. The
participants in the prehypertensive group will not receive any medication, while those in the stage 1 hypertensive
group will continue to receive their routine medications during the study. Blood samples will be taken from all groups
and examined for various biochemical parameters.
Discussion: This trial will help to establish whether resveratrol is an effective antihypertensive agent in prehypertensive
and stage 1-hypertensive patients. The trial outcome will provide novel insight into the clinical efficacy of resveratrol
and provide valuable information for conducting future clinical studies with resveratrol.
Trial registration: Iranian Registry of Clinical Trials, IRCT201407078129N7. Registered on 15 August 2014.
Keywords: Resveratrol, Hypertension, Blood pressure, Polypheno
Are the cardioprotective effects of the phytoestrogen resveratrol sex dependent?
Cardiovascular disease (CVD) is the number one cause of death in both men and women. Younger women have a lower risk for CVD, but their risk increases considerably after menopause when estrogen levels decrease. The cardiovascular protective properties of estrogen are mediated through decreasing vascular inflammation and progression of atherosclerosis, decreasing endothelial cell damage by preventing apoptosis and anti-hypertrophic mechanisms. Estrogen also regulates glucose and lipid levels which are two important risk factors for CVD. Resveratrol (RES), a cardioprotective polyphenolic compound is classified as a phytoestrogen due its capacity to bind to and modulate estrogen receptor signaling. Due to its estrogen like property, we speculate that the cardioprotective effects of RES treatment could be sex dependent. Based on earlier reports and more recent data from our lab presented here, we found that RES treatment may have more favourable cardiovascular outcomes in females when compared to males. This review will discuss estrogen and phytoestrogens such as RES, mediated cardioprotection with a specific focus on sex dependent effects reported in preclinical and clinical studies.The accepted manuscript in pdf format is listed with the files at the bottom of this page. The presentation of the authors' names and (or) special characters in the title of the manuscript may differ slightly between what is listed on this page and what is listed in the pdf file of the accepted manuscript; that in the pdf file of the accepted manuscript is what was submitted by the author
Pro-apoptotic versus anti-apoptotic properties of dietary resveratrol on tumoral and normal cardiac cells
Resveratrol is a natural dietary polyphenol found in grape skin, red wine, and various other food products. Resveratrol has proved to be an effective chemopreventive agent for different malignant tumors. It has also been shown to prevent vascular alterations such as atherosclerosis and inflammatory-associated events. In view of these observations, we investigated the anti-proliferative and pro-apoptotic activities of resveratrol on a tumoral cardiac cell line (HL-1 NB) derived from mouse tumoral atrial cardiac myocytes. These effects were compared with those found on normal neonatal mouse cardiomyocytes. HL-1 NB cells and neonatal cardiomyocytes were treated with resveratrol (5, 30, and/or 100 μM) for different times of culture (24, 48, and/or 72 h). Resveratrol effects were determined by various microscopical and flow cytometric methods. After resveratrol treatment, a strong inhibition of tumoral cardiac HL1-NB cell growth associated with a loss of cell adhesion was observed. This cell proliferation arrest was associated with an apoptotic process revealed by an increased percentage of cells with fragmented and/or condensed nuclei (characteristic of apoptotic cells) identified after staining with Hoechst 33342 and by the presence of cells in subG1. At the opposite, on normal cardiomyocytes, no cytotoxic effects of resveratrol were observed, and a protective effect of resveratrol against norepinephrine-induced apoptosis was found on normal cardiomyocytes. Altogether, the present data demonstrate that resveratrol (1) induces apoptosis of tumoral cardiac HL1-NB cells, (2) does not induce cell death on normal cardiomyocytes, and (3) prevents norepinephrine-induced apoptosis on normal cardiomyocytes